Zongru Li
Qingdao University(CN)Peking University(CN)Kyushu Institute of Technology(JP)China-Japan Friendship Hospital(CN)Peking University People's Hospital(CN)National Clinical Research(US)Yulin Orthopedics Hospital of Chinese and Western Medicine(CN)Tokyo University of Agriculture and Technology(JP)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Eosinophilic Disorders and Syndromes
Most-Cited Works
- → Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial(2022)93 cited
- → Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody(2021)38 cited
- → Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials(2020)26 cited
- → Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy(2020)19 cited
- → Interaction+: Interaction enhancement for web-based visualizations(2017)16 cited
- → Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)